Abstract: A wireless charging device includes a shell, a coil assembly, a main board assembly and a heat dissipation assembly. The shell is defined with first and second air ports, the coil assembly and the main board assembly are located in the shell, the heat dissipation assembly is used for dissipating heat of the coil assembly and the main board assembly. The heat dissipation assembly includes a heat sink and a fan, the heat sink includes a first side and a second side facing away from each other, the coil assembly is arranged on the first side, the fan is arranged on the second side, and the fan is defined with third and fourth air ports. The first air port, the second air port, the third air port and the fourth air port are in communication with one another to form a heat-dissipation air passage located on the second side.

Abstract: A wireless charging device includes a shell, a coil assembly, a main board assembly and a heat dissipation assembly. The shell is defined with first and second air ports, the coil assembly and the main board assembly are located in the shell, the heat dissipation assembly is used for dissipating heat of the coil assembly and the main board assembly. The heat dissipation assembly includes a heat sink and a fan, the heat sink includes a first side and a second side facing away from each other, the coil assembly is arranged on the first side, the fan is arranged on the second side, and the fan is defined with third and fourth air ports. The first air port, the second air port, the third air port and the fourth air port are in communication with one another to form a heat-dissipation air passage located on the second side.

Abstract: This application discloses a media file presentation method, a client application, and a plug-in. The method includes: sending a media information obtaining request to a plug-in installed in the client application, so that the plug-in obtains first brief information and second brief information of a media file from a server based on the media information obtaining request; and receiving a notification message for the media file from the plug-in; and presenting the first brief information at a first presentation position according to the notification message, and then presenting the second brief information at a second presentation position, the media file being obtained and presented when an operation performed by a user on the second brief information is received.

Abstract: The present disclosure discloses a media information processing method, a mobile terminal, and a storage medium. The method includes: determining that a condition for presenting media information in a graphical interface of an application is satisfied; requesting media information and a control policy of the media information from a server; loading the control policy in the application, and determining that a form needs to be used in the media information to obtain information from a user; requesting a WebView page adapted to the form from the server, the WebView page being obtained by initializing a WebView template based on a customized parameter of the form; and presenting the media information in the graphical interface of the application, and loading the WebView page in the graphical interface of the application.

Abstract: The present disclosure discloses a media information processing method, a mobile terminal, and a storage medium. The method includes: determining that a condition for presenting media information in a graphical interface of an application is satisfied; requesting media information and a control policy of the media information from a server; loading the control policy in the application, and determining that a form needs to be used in the media information to obtain information from a user; requesting a WebView page adapted to the form from the server, the WebView page being obtained by initializing a WebView template based on a customized parameter of the form; and presenting the media information in the graphical interface of the application, and loading the WebView page in the graphical interface of the application.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTTG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in diagnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Disclosed is a transgenic non-human mammal, which carries in its cells an exogenously supplied rat pituitary tumor transforming gene (PTTG) polynucleotide sequence.

Abstract: Disclosed is a transgenic non-human mammal, which carries in its cells an exogenously supplied human pituitary tumor transforming gene (PTTG) polynucleotide sequence.

Abstract: PTTG polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to a method of producing PTTG polypeptide, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or be carried by a recombinant host cell. PTTG oligonucleotide probes and primers are disclosed, which can be employed in diagnostic kits, in methods of identifying or isolating mammalian PTTG nucleic acid, and in a method for detecting a pathological mass associated with PTTG expression. An antisense oligonucleotide is disclosed. Compositions comprising PTTG nucleic acids are also disclosed.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encode them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in disgnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

Abstract: The invention provides anti-Axl antibodies and methods of using the same.